Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sansure Biotech Inc. (688289.SS)
Changsha, CN
Sansure Biotech Inc., founded in Changsha, China, in 2008, is dedicated to the global development and commercialization of advanced diagnostic and research products. The company offers a diverse range of solutions, including upstream nucleic acid extraction kits, real-time PCR systems for both clinical and investigative purposes, and fluorescence detection platforms. Their extensive product portfolio encompasses diagnostic assays for critical conditions like the novel coronavirus, viral hepatitis, and AIDS. Furthermore, they provide blood screening and general extraction kits, tests for cancer-related biomarkers, and solutions for respiratory, sexually transmitted, digestive tract, prenatal, postnatal, and genetic diseases. Sansure Biotech also supplies essential laboratory instrumentation and various consumables, primarily serving hospitals and scientific laboratories worldwide.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.53% | +2.69% | -0.66% | -6.94% | -17.53% | -4.97% | -10.46% | -1.70% | -73.55% | -77.08% | -77.08% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+13.0% ★ Q1'26: -8.0% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-27.7% Q1'26: -50.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+0.3% Q1'26: -13.7% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+10.6% Q1'26: +13.2% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+4.2% Q1'26: +4.2% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.6% ★ Q1'26: +8.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×3.39× ★ Q1'26: 5.21× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
4.76B
est: 4.89B (-2.5%)
|
4.51B
est: 4.65B (-2.9%)
|
6.45B
est: 5.24B (+23.1%)
|
1.01B
est: 1.01B (-0.1%)
|
1.46B
est: 1.51B (-3.6%)
|
1.65B
est: 1.66B (-1.0%)
|
1.95B
1.82B – 2.02B
+17.1% YoY
|
2.35B
2.08B – 2.50B
+20.4% YoY
|
| EBITDA |
3.10B
est: 1.79B (+72.8%)
|
2.66B
est: 1.71B (+56.1%)
|
2.39B
est: 1.92B (+24.5%)
|
516.89M
est: 369.83M (+39.8%)
|
419.64M
est: 591.16M (-29.0%)
|
315.98M
est: 650.40M (-51.4%)
|
761.88M
712.97M – 790.10M
+17.1% YoY
|
917.22M
813.22M – 977.24M
+20.4% YoY
|
| EBIT |
3.07B
est: 1.57B (+95.1%)
|
2.62B
est: 1.50B (+74.8%)
|
2.32B
est: 1.69B (+37.3%)
|
416.01M
est: 324.66M (+28.1%)
|
279.01M
est: 499.25M (-44.1%)
|
175.35M
est: 549.27M (-68.1%)
|
643.42M
602.12M – 667.26M
+17.1% YoY
|
774.62M
686.78M – 825.30M
+20.4% YoY
|
| Net Income |
2.62B
est: 2.66B (-1.5%)
|
2.24B
est: 2.28B (-1.8%)
|
1.94B
est: 2.13B (-8.9%)
|
363.72M
est: 359.10M (+1.3%)
|
275.60M
est: 281.61M (-2.1%)
|
198.15M
est: 214.69M (-7.7%)
|
282.00M
264.41M – 302.38M
+31.4% YoY
|
387.33M
313.05M – 419.17M
+37.4% YoY
|
| SGA |
601.13M
est: 1.40B (-57.0%)
|
485.51M
est: 1.33B (-63.5%)
|
936.84M
est: 1.50B (-37.5%)
|
543.54M
est: 288.35M (+88.5%)
|
746.00M
est: 463.92M (+60.8%)
|
377.97M
est: 510.40M (-25.9%)
|
597.89M
559.51M – 620.03M
+17.1% YoY
|
719.80M
638.18M – 766.89M
+20.4% YoY
|
| EPS |
4.74
est: 4.51 (+5.0%)
|
3.81
est: 3.88 (-1.8%)
|
3.31
est: 3.61 (-8.3%)
|
0.62
est: 0.61 (+1.6%)
|
0.47
est: 0.49 (-3.6%)
|
0.34
est: 0.38 (-9.3%)
|
0.50
0.45 – 0.52
+32.0% YoY
|
0.61
0.54 – 0.72
+23.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 142.4K | 0.39% |
| 2 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 150.2K | 0.06% |
| 3 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 59.8K | 0.17% |
| 4 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 59.8K | 0.17% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 11.5K | 0.48% |
| 6 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 26.0K | 0.26% |
| 7 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.28M | 0.06% |
| 8 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 15.6K | 0.46% |
| 9 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 57.4K | 0.29% |
| 10 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 68.7K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Haixiao Wang | Deputy General Manager | — | male |
| Jia Liu | Deputy GM & Director | — | male |
| Jun Zhou | Deputy General Manager | — | female |
| Kai Liu | Deputy General Manager | — | male |
| Lizhong Dai | Chairman of the Board & GM | — | male |
| Qiang Huang | Secretary | — | male |
| Xialin Yu | Deputy GM & Director | — | male |
| Xiaoyan Xiong | Deputy General Manager | — | female |
| Zhongping Deng | Deputy General Manager | — | male |
| Zhu Peng | Chief Financial Officer, Deputy GM & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688289.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
